Published in Circulation on October 11, 2005
Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation (2005) 1.59
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med (2004) 7.12
Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker. N Engl J Med (2015) 4.26
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation (2010) 3.17
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc (2002) 2.67
Commotio cordis. N Engl J Med (2010) 2.67
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation (2003) 2.56
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2011) 2.48
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 2.23
Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm (2010) 2.15
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace (2013) 1.97
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87
Clinical profile and spectrum of commotio cordis. JAMA (2002) 1.86
Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation (2009) 1.85
High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST). J Am Coll Cardiol (2004) 1.83
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol (2009) 1.83
Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation (2004) 1.82
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm (2008) 1.72
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.65
ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol (2008) 1.60
Preserved heart rate variability identifies low-risk patients with nonischemic dilated cardiomyopathy: results from the DEFINITE trial. Heart Rhythm (2006) 1.55
Preventing sudden cardiac death: can we afford the benefit? Ann Intern Med (2005) 1.55
Incidence and significance of pacemaker and implantable cardioverter-defibrillator lead masses discovered during transesophageal echocardiography. Pacing Clin Electrophysiol (2011) 1.54
Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm (2009) 1.51
Clinical decisions. Cardiac screening before participation in sports. N Engl J Med (2013) 1.51
One conversion of ventricular fibrillation is adequate for implantable cardioverter-defibrillator implant: an analysis from the Low Energy Safety Study (LESS). Heart Rhythm (2005) 1.50
Death in a young athlete due to commotio cordis despite prompt external defibrillation. Heart Rhythm (2005) 1.48
Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol (2008) 1.47
Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J (2004) 1.47
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace (2012) 1.46
The automated external defibrillator: clinical benefits and legal liability. JAMA (2006) 1.46
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2012) 1.45
Increasing survival rate from commotio cordis. Heart Rhythm (2012) 1.45
Equivalent arrhythmic risk in patients recently diagnosed with dilated cardiomyopathy compared with patients diagnosed for 9 months or more. Heart Rhythm (2006) 1.40
Variant angina associated with bitter orange in a dietary supplement. Mayo Clin Proc (2006) 1.40
Inducible ventricular flutter and fibrillation predict for arrhythmia occurrence in coronary artery disease patients presenting with syncope of unknown origin. J Cardiovasc Electrophysiol (2002) 1.38
Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation (2010) 1.31
Task Force 7: arrhythmias. J Am Coll Cardiol (2005) 1.30
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2015) 1.26
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. Eur Heart J (2011) 1.25
Upper and lower limits of vulnerability to sudden arrhythmic death with chest-wall impact (commotio cordis). J Am Coll Cardiol (2003) 1.24
Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation (2003) 1.20
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace (2015) 1.13
Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines: developed in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm (2009) 1.12
Interpretation of the electrocardiogram of young athletes. Circulation (2011) 1.10
Durability of repaired sensing leads equivalent to that of new leads in implantable cardioverter defibrillator patients with sensing abnormalities. Pacing Clin Electrophysiol (2003) 1.08
Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm (2008) 1.05
Ablation after ICD implantation--bridging the gap between promise and practice. N Engl J Med (2007) 1.05
Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation (2013) 1.04
Heart Rhythm Society Policy Statement Update: Recommendations on the Role of Industry Employed Allied Professionals (IEAPs). Heart Rhythm (2008) 1.04
Arrhythmogenic right ventricular cardiomyopathy/dysplasia: risk stratification and therapy. Prog Cardiovasc Dis (2007) 1.04
Commotio cordis--sudden cardiac death with chest wall impact. J Cardiovasc Electrophysiol (2007) 1.02
ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation (2008) 0.99
Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc (2005) 0.98
Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. Am Heart J (2008) 0.98
Sudden cardiac death in athletes. Curr Cardiol Rep (2006) 0.98
American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation (2011) 0.97
Timing cycles for biventricular pacing. Pacing Clin Electrophysiol (2002) 0.96
Cell membrane stretch and chest blow-induced ventricular fibrillation: commotio cordis. J Cardiovasc Electrophysiol (2008) 0.96
Failure of commercially available chest wall protectors to prevent sudden cardiac death induced by chest wall blows in an experimental model of commotio cordis. Pediatrics (2006) 0.96
Effectiveness of automated external defibrillators in high schools in greater Boston. Am J Cardiol (2005) 0.95
Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. Am Heart J (2011) 0.95
Evaluation of chest barriers for protection against sudden death due to commotio cordis. Am J Cardiol (2007) 0.95
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.94
Role of streptomycin-sensitive stretch-activated channel in chest wall impact induced sudden death (commotio cordis). J Cardiovasc Electrophysiol (2005) 0.92
Commotio cordis and the epidemiology of sudden death in competitive lacrosse. Pediatrics (2009) 0.92
Task Force 10: automated external defibrillators. J Am Coll Cardiol (2005) 0.91
A summary of the update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. J Am Dent Assoc (2011) 0.91
Relation of 12-lead electrocardiogram patterns to implanted defibrillator-terminated ventricular tachyarrhythmias in hypertrophic cardiomyopathy. Am J Cardiol (2009) 0.90
Short QT syndrome review. J Interv Card Electrophysiol (2008) 0.90
Sudden cardiac death in the athlete: bridging the gaps between evidence, policy, and practice. Circulation (2012) 0.89
Echocardiographic evidence of left atrial abnormality in young patients with lone paroxysmal atrial fibrillation. Am J Cardiol (2004) 0.88
The short QT syndrome. J Interv Card Electrophysiol (2011) 0.88